Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Comply With EU MDD Or MDR? Your Multi-Year Decision Is Beset With Hazards

Executive Summary

Will it be better to continue compliance under the Medical Devices Directive or switch to compliance under the new Medical Devices Regulation when there is a choice? The pros and cons make it a difficult decision.

You may also be interested in...

Where To Turn For Help On The Imminent EU Regulations

The countdown to the new EU Regulations taking effect is nearly over. Where can you get advice? This article provides you with some useful resources, including conferences and webinars, to help get started.

European Commission: Timing And Priorities For Regulation Implementation

The European Commissioner recently laid out more specifics on its anticipated timing for the roll-out of key priorities in the implementation of the EU Medical Device and IVD Regulations.

Brexit And The Regulatory Question: Where Are We Now?

The UK needs the EU Medical Device Regulation. Logic dictates it and there are signs the country will adhere to these new upcoming rules – yet nothing is certain.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts